DEVELOPMENT OF A DE NOVO MODEL TO ASSESS THE COST-EFFECTIVENESS OF A NEW TREATMENT OPTION FOR PATIENTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN)

被引：0
|
作者：
Davies, N. [1 ]
Dickinson, O. [1 ]
Downward, L. [2 ]
Pitcher, D. [2 ]
Gale, D. [3 ]
Ioannou, P. [1 ]
Kipentzoglou, K. [4 ]
Crabtree, M. [5 ]
机构：
[1] Mtech Access Ltd, Bicester, England
[2] UK Renal Registry, Bristol, BST, England
[3] UCL, London, England
[4] Britannia Pharmaceut Ltd, Reading, England
[5] STADA, Bad Vilbel, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE119
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [41] Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease
    Michael Spencer
    Andrew H. Briggs
    Ronald F. Grossman
    Laureen Rance
    PharmacoEconomics, 2005, 23 : 619 - 637
  • [42] RATIONALITY AND COST-EFFECTIVENESS OF DIAGNOSIS AND TREATMENT OF GROUP-A STREPTOCOCCI IN PRIMARY CARE PATIENTS WITH PHARYNGITIS
    MAKELA, M
    SINTONEN, H
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1991, 23 (01) : 47 - 53
  • [43] COST-EFFECTIVENESS OF FLUTICASONE FUROATE COMPARED WITH MOMETASONA FUROATE FOR THE PRIMARY TREATMENT OF ALLERGIC RHINITIS PATIENTS
    Rely, K.
    Alexandre, P. K.
    Anaya, P.
    Salinas, G. E.
    VALUE IN HEALTH, 2011, 14 (07) : A566 - A566
  • [44] Designing and Testing of a Health-Economic Markov Model to Assess Cost-Effectiveness of the Treatment of Bipolar Disorder: TiBiPoMod
    Kleijburg, Anne
    Lokkerbol, Joran
    Wijnen, Ben
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2022, 25 : S20 - S20
  • [45] A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients
    Knoester, Pieter D.
    Deckers, Charles L. P.
    Termeer, Eveline H.
    Boendermaker, Arjo J.
    Kotsopoulos, Irene A. W.
    de Krom, Marc C. T. F. M.
    Keyser, Toine
    Renier, Willy O.
    Hekster, Yechiel A.
    Severens, Hans L.
    VALUE IN HEALTH, 2007, 10 (03) : 173 - 182
  • [46] Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder
    Lokkerbol, Joran
    Wijnen, Ben
    Ruhe, Henricus G.
    Spijker, Jan
    Morad, Arshia
    Schoevers, Robert
    de Boer, Marrit K.
    Cuijpers, Pim
    Smit, Filip
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1031 - 1042
  • [47] The German Cardiometabolic Cost Database - A methodological approach to assess cost data for modelling cost-effectiveness of treatment regimes for patients with multiple cardiometabolic risk factors
    Fuchs, S. M.
    Klauss, V
    Dieterle, C.
    Wasem, J.
    Aidelsburger, P.
    VALUE IN HEALTH, 2006, 9 (06) : A360 - A360
  • [48] Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy
    Cairoli, Roberto
    Furneri, Gianluca
    Di Virgilio, Roberto
    Veggia, Barbara
    Ferrara, Felicetto
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [49] Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy
    Roberto Cairoli
    Gianluca Furneri
    Roberto Di Virgilio
    Barbara Veggia
    Felicetto Ferrara
    BMC Health Services Research, 23
  • [50] aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model
    Kim, Chong H.
    Simmons, Sierra C.
    Bui, Chau M.
    Jiang, Ning
    Pham, Huy P.
    VOX SANGUINIS, 2019, 114 (01) : 63 - 72
12345